Top

Published in:

01-04-2013 | Original Article

Quality of life outcomes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a controlled comparison

Authors: Kristin M. Phillips, Javier Pinilla-Ibarz, Eduardo Sotomayor, Morgan R. Lee, Heather S. L. Jim, Brent J. Small, Lubomir Sokol, Jeffrey Lancet, Sara Tinsley, Kendra Sweet, Rami Komrokji, Paul B. Jacobsen

Published in: Supportive Care in Cancer | Issue 4/2013

Abstract

Purpose

Tyrosine kinase inhibitors (TKIs) are now standard treatment for chronic myeloid leukemia (CML). While TKIs have less toxicity than previous treatments, they have side effects that can impact quality of life (QOL).

Methods

This study compared CML patients taking a TKI for an average of 4.01 years (range 0.50–9.79 years) to age- and gender-matched controls with no history of cancer on measures of symptom burden, depression, fatigue, sleep, and health-related QOL.

Results

Compared to controls (n = 62), CML patients (n = 62) taking a TKI (imatinib 55 %, nilotinib 31 %, and dasatinib 14 %) reported significantly worse fatigue severity (p < .001), fatigue interference (p < .001), depression (p = .007), symptom burden (p < .001), and physical QOL (p < .001). TKI patients were also more likely meet established cutoffs for clinically meaningful fatigue (p values < .001) and depression (p = .004). There were no differences in mental QOL or sleep (p values > .010). Regarding specific symptoms, TKI patients were more likely to report nausea, diarrhea, itching, skin changes, swelling of arms or legs, and not looking like themselves (p values < .001).

Conclusions

These data suggest the need for interventions to address QOL in CML patients taking TKIs.

O'Brien SG, Guilhot F, Larson RA et al (2003) Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 348(11):994–1004PubMedCrossRef

Hahn EA, Glendenning GA, Sorensen MV et al (2003) Quality of life in patients with newly diagnosed chronic phase chronic myeloid leukemia on imatinib versus interferon alfa plus low-dose cytarabine: results from the IRIS Study. J Clin Oncol 21(11):2138–2146PubMedCrossRef

Aziz Z, Iqbal J, Aaqib M et al (2011) Assessment of quality of life with imatinib mesylate as first-line treatment in chronic phase-chronic myeloid leukemia. Leuk Lymphoma 52(6):1017–1023PubMedCrossRef

Agrawal M, Garg RJ, Cortes J et al (2010) Tyrosine kinase inhibitors: the first decade. Curr Hematol Malig Rep 5(2):70–80PubMedCrossRef

Pinilla-Ibarz J, Cortes J, Mauro MJ (2011) Intolerance to tyrosine kinase inhibitors in chronic myeloid leukemia: definitions and clinical implications. Cancer 117(4):688–697PubMedCrossRef

Efficace F, Baccarani M, Breccia M et al (2011) Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population. Blood 118(17):4554–4560PubMedCrossRef

Apolone G, Mosconi P (1998) The Italian SF-36 Health Survey: translation, validation and norming. J Clin Epidemiol 51(11):1025–1036PubMedCrossRef

Jacobsen PB, Donovan KA, Small BJ et al (2007) Fatigue after treatment for early stage breast cancer: a controlled comparison. Cancer 110(8):1851–1859PubMedCrossRef

Hann DM, Jacobsen PB, Azzarello LM et al (1998) Measurement of fatigue in cancer patients: development and validation of the Fatigue Symptom Inventory. Qual Life Res 7(4):301–310PubMedCrossRef

10.

Broeckel JA, Jacobsen PB, Horton J et al (1998) Characteristics and correlates of fatigue after adjuvant chemotherapy for breast cancer. J Clin Oncol 16(5):1689–1696PubMed

11.

Donovan KA, Jacobsen PB, Small BJ et al (2008) Identifying clinically meaningful fatigue with the Fatigue Symptom Inventory. J Pain Symptom Manage 36(5):480–487PubMedCrossRef

12.

Radloff LS (1977) The CES-D scale: a self-report depression scale for research in the general population. Appl Psychol Meas 1:385–401CrossRef

13.

Hann D, Winter K, Jacobsen P (1999) Measurement of depressive symptoms in cancer patients: evaluation of the Center for Epidemiological Studies Depression Scale (CES-D). J Psychosom Res 46(5):437–443PubMedCrossRef

14.

Buysse DJ, Reynolds CF 3rd, Monk TH et al (1989) The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res 28(2):193–213PubMedCrossRef

15.

Carpenter JS, Andrykowski MA (1998) Psychometric evaluation of the Pittsburgh Sleep Quality Index. J Psychosom Res 45(1):5–13PubMedCrossRef

16.

Beck SL, Schwartz AL, Towsley G et al (2004) Psychometric evaluation of the Pittsburgh Sleep Quality Index in cancer patients. J Pain Symptom Manage 27(2):140–148PubMedCrossRef

17.

Chang VT, Hwang SS, Feuerman M et al (2000) The memorial symptom assessment scale short form (MSAS-SF). Cancer 89(5):1162–1171PubMedCrossRef

18.

Ware J (1993) SF-36 health survey: Manual and interpretation guide. The Health Institute, New England Medical Center, Boston

19.

Ware JE, Kosinski M, Keller SD (1994) SF-36 pysical and mental health summary scales: A user's manual. The Health Institute, New England Medical Center, Boston

20.

Cohen J (1988) Statistical power analysis for the behavioral sciences. Lawrence Erlbaum Associates

21.

Gambacorti-Passerini C, Antolini L, Mahon FX et al (2011) Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib. J Natl Cancer Inst 103(7):553–561PubMedCrossRef

22.

Saglio G, Kim DW, Issaragrisil S et al (2010) Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 362(24):2251–2259PubMedCrossRef

23.

Masiello D, Gorospe G 3rd, Yang AS (2009) The occurrence and management of fluid retention associated with TKI therapy in CML, with a focus on dasatinib. J Hematol Oncol 2:46PubMedCrossRef

Title: Quality of life outcomes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a controlled comparison
Authors: Kristin M. Phillips
Javier Pinilla-Ibarz
Eduardo Sotomayor
Morgan R. Lee
Heather S. L. Jim
Brent J. Small
Lubomir Sokol
Jeffrey Lancet
Sara Tinsley
Kendra Sweet
Rami Komrokji
Paul B. Jacobsen
Publication date: 01-04-2013
Publisher: Springer-Verlag
Published in: Supportive Care in Cancer / Issue 4/2013
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI: https://doi.org/10.1007/s00520-012-1630-5

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 4/2013

Longitudinal prospective assessment of sleep quality: before, during, and after adjuvant chemotherapy for breast cancer

Improving access to specialist multidisciplinary palliative care consultation for rural cancer patients by videoconferencing: report of a pilot project

A proposal for a simplified MASCC score

Predictors of high score patient-reported barriers to controlling cancer pain: a preliminary report

The use of Ginkgo biloba for the prevention of chemotherapy-related cognitive dysfunction in women receiving adjuvant treatment for breast cancer, N00C9

The protective effects of glutamine on radiation-induced diarrhea

Keynote webinar | Spotlight on antibody–drug conjugates in cancer